Ilunocitinib (LY3411067) is a Janus kinase (JAK) inhibitor developed for veterinary use, specifically for treating allergic and inflammatory skin conditions in dogs, such as canine atopic dermatitis. It selectively inhibits JAK1, with a high degree of selectivity over JAK2, JAK3, and TYK2, aiming to reduce pruritus and inflammation by blocking cytokine signaling involved in allergic responses (e.g., IL-2, IL-6, IL-13, and IFN-γ). Preclinical pharmacology data show an IC₅₀ for JAK1 in the low nanomolar range (~10–20 nM) and reduced activity toward hematopoietic and immune regulation-related kinases, limiting adverse effects like anemia or immunosuppression..
MedKoo Cat#: 465393
Name: Ilunocitinib
CAS#: 1187594-14-4
Chemical Formula: C17H17N7O2S
Exact Mass: 383.1164
Molecular Weight: 383.43
Elemental Analysis: C, 53.25; H, 4.47; N, 25.57; O, 8.35; S, 8.36
The following data is based on the product molecular weight 383.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
